NasdaqGS - Delayed Quote USD

Roivant Sciences Ltd. (ROIV)

11.18 +0.05 (+0.45%)
At close: 4:00 PM EDT
11.05 -0.13 (-1.16%)
After hours: 4:41 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
3/31/2023
3/31/2022
3/31/2021
Total Revenue
123,241.00
61,280.00
55,286.00
23,795.00
Cost of Revenue
15,323.00
13,128.00
8,966.00
2,057.00
Gross Profit
107,918.00
48,152.00
46,320.00
21,738.00
Operating Expense
1,156,028.00
1,125,721.00
1,258,068.00
496,504.00
Operating Income
-1,048,110.00
-1,077,569.00
-1,211,748.00
-474,766.00
Net Non Operating Interest Income Expense
41,073.00
4,216.00
-6,672.00
-1,391.00
Other Income Expense
5,272,704.00
-151,481.00
294,673.00
-422,390.00
Pretax Income
4,265,667.00
-1,224,834.00
-923,747.00
-898,547.00
Tax Provision
27,388.00
5,190.00
369.00
1,686.00
Net Income Common Stockholders
4,466,424.00
-1,009,030.00
-845,262.00
-809,234.00
Diluted NI Available to Com Stockholders
4,466,424.00
-1,009,030.00
-845,262.00
-809,234.00
Basic EPS
5.76
-1.42
-1.26
-1.18
Diluted EPS
5.43
-1.42
-1.26
-1.18
Basic Average Shares
768,069.83
712,791.12
669,753.46
684,789.17
Diluted Average Shares
803,732.55
712,791.12
669,753.46
684,789.17
Total Operating Income as Reported
4,273,850.00
-1,175,318.00
-1,351,642.00
-1,070,898.00
Total Expenses
1,171,351.00
1,138,849.00
1,267,034.00
498,561.00
Net Income from Continuing & Discontinued Operation
4,466,424.00
-1,009,030.00
-845,262.00
-809,234.00
Normalized Income
-921,953.30
-1,051,267.72
-1,078,608.42
-497,193.65
Interest Income
77,251.00
32,184.00
369.00
1,418.00
Interest Expense
36,178.00
27,968.00
7,041.00
2,809.00
Net Interest Income
41,073.00
4,216.00
-6,672.00
-1,391.00
EBIT
4,301,845.00
-1,196,866.00
-916,706.00
-895,738.00
EBITDA
4,324,609.00
-1,178,009.00
-910,774.00
-895,738.00
Reconciled Cost of Revenue
15,323.00
13,128.00
8,966.00
2,057.00
Reconciled Depreciation
22,764.00
18,857.00
5,932.00
--
Net Income from Continuing Operation Net Minority Interest
4,351,863.00
-1,123,591.00
-845,262.00
-809,234.00
Total Unusual Items Excluding Goodwill
5,307,896.00
-89,288.00
288,082.00
-385,235.00
Total Unusual Items
5,307,896.00
-89,288.00
288,082.00
-385,235.00
Normalized EBITDA
-983,287.00
-1,088,721.00
-1,198,856.00
-510,503.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
34,079.70
-16,964.72
54,735.58
-73,194.65
3/31/2021 - 12/8/2020

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

BBIO BridgeBio Pharma, Inc.
28.50
-2.06%
 
IMVT Immunovant, Inc.
29.88
+1.67%
 
CYTK Cytokinetics, Incorporated
57.89
-6.78%
 
ABUS Arbutus Biopharma Corporation
2.8900
+0.35%
 
TIL Instil Bio, Inc.
11.80
+1.90%
 
LEGN Legend Biotech Corporation
42.97
-0.62%
 
RPRX Royalty Pharma plc
28.38
+1.03%
 
SPRO Spero Therapeutics, Inc.
1.6500
+0.61%
 
ASND Ascendis Pharma A/S
132.02
-1.08%
 
KRYS Krystal Biotech, Inc.
154.82
+0.04%